Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Wassil Nowicky

Wassil Nowicky

"Nowicky Pharma”/ Ukrainian Anti-Cancer Institute, Margareten Street 7, A-1040, Vienna, Austria

Title: Selective and immunomodulating properties of the anticancer proton preparation on basis of Greater Celandine Alkaloids NSC631570

Biography

Biography: Wassil Nowicky

Abstract

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. Until now this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC 631570 killed only cancer cells without having damaged the normal cells what confirmed its selective effect.